| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 17,673 | - |
| Depreciation and amortization | 8,281 | - |
| Stock-based compensation | 5,327 | - |
| Provision for credit loss recovery | -362 | - |
| Disposal of property and equipment | -4 | - |
| Accounts receivable, net | 1,192 | - |
| Inventory, net | 752 | - |
| Prepaid expenses and other | -393 | - |
| Other current assets | 139 | - |
| Accounts payable | 877 | - |
| Operating lease assets and liabilities, net | 1,266 | - |
| Accrued expenses and other | 279 | - |
| Post-marketing commitment liability | -1,740 | - |
| Net cash provided by operating activities | 27,383 | 17,694 |
| Purchase of property and equipment | 107 | 81 |
| Purchase of available-for-sale securities | 61,204 | 34,420 |
| Maturity of available-for-sale securities | 52,100 | 24,784 |
| Net cash used in investing activities | -9,211 | -9,717 |
| Net proceeds from shares issued under employee stock plans | 130 | 130 |
| Payment of debt | 33,330 | 22,220 |
| Payment of exit costs | 666 | 444 |
| Net cash used in financing activities | -33,866 | -22,534 |
| Net decrease in cash, cash equivalents and restricted cash | -15,694 | -14,557 |
| Cash and cash equivalents at beginning of period | 71,310 | - |
| Cash and cash equivalents at end of period | 55,616 | - |
PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI)